Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial

BACKGROUND: The PROPKD score has been proposed to stratify the risk of progression to end-stage renal disease in autosomal dominant polycystic kidney disease (ADPKD) subjects. We aimed to assess its prognostic value in a genotyped subgroup of subjects from the Tolvaptan Phase 3 Efficacy and Safety S...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nephrol Dial Transplant
Main Authors: Cornec-Le Gall, Emilie, Blais, Jaime D, Irazabal, Maria V, Devuyst, Olivier, Gansevoort, Ron T, Perrone, Ron D, Chapman, Arlene B, Czerwiec, Frank S, Ouyang, John, Heyer, Christina M, Senum, Sarah R, Le Meur, Yannick, Torres, Vicente E, Harris, Peter C
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
ORIGINAL ARTICLES
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5888998/
https://ncbi.nlm.nih.gov/pubmed/28992127
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ndt/gfx188
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados